NCT06167486View on ClinicalTrials.gov

SG2918 For Advanced Malignant Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

December 26, 2023

Primary Completion Date

December 28, 2025

Study Completion Date

December 28, 2026

Conditions
Advanced Malignant Tumors
Interventions
DRUG

SG2918

The SG2918 will be administrated by intravenous infusion every 3 weeks

Trial Locations (6)

30013

RECRUITING

Shanxi Provincial Cancer Hospital, Taiyuan

200126

RECRUITING

Shanghai first maternity and infant hospital, Shanghai

310005

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

400000

RECRUITING

Chongqing University Cancer Hospital, Chongqing

410031

RECRUITING

Hunan Cancer Hospital, Changsha

450003

RECRUITING

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

Hangzhou Sumgen Biotech Co., Ltd.

INDUSTRY